newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

  • Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) announced that President & CEO Jayson Rieger, PhD, MBA will present at the 25th Annual Needham Virtual Healthcare Conference.
  • The presentation is scheduled for Wednesday, April 15, 2026, at 3:00pm ET.
  • The event is virtual, with a live webcast accessible via a provided link or the Investors/Presentations & Events section of www.verrica.com.
  • A replay of the webcast will be posted shortly after the event and remain available for 90 days.
  • Verrica is developing treatments for dermatological diseases, including skin cancers.
  • YCANTH® (VP-102) is the first FDA-approved healthcare professional-administered treatment for molluscum contagiosum in adults & children aged two & older.
  • YCANTH® is also in development to treat common warts.
  • Verrica holds a worldwide license agreement with Lytix Biopharma AS to develop VP-315 (ruxotemitide) for non-melanoma skin cancers.